Breast Cancer Implementation Science Study With Educational Intervention
A study uniquely focused on system-based practice change, measuring the impact of educational interventions on both patients and clinicians for the recognition and management of treatment-related adverse effects for HER2+/HER2 low breast cancer patients on or about to start on HER2 targeted antibody drug conjugates (fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine) and shared decision-making methodologies to improve adverse event (AE) management and patient-clinician communications.
Conditions studied
Breast Cancer
About this study
A study uniquely focused on system-based practice change, measuring the impact of educational interventions on both patients and clinicians for the recognition and management of treatment-related adverse effects for HER2+/HER2 low breast cancer patients on or about to start on HER2 targeted antibody drug conjugates (fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine) and shared decision-making methodologies to improve adverse event (AE) management and patient-clinician communications.
Interventions
- Behavioral: Educational Intervention — The research-specific educational intervention is the enhancement of communications and SDM in AE management. To this end, interventions will include pre-recorded videos that address: 1. SDM methodologies (\~30 minutes) 2. Simulated case role play interactions between a standardized patient actor and clinician participant (\~60 minutes) 3. In depth presentation on AEs associated with HER2-targeted ADC treatments, and the management of these AEs (\~45 minutes) Clinician participant educational intervention videos and patient participant educational intervention videos will be slightly different, as they are each presented from their specific perspectives.
Primary outcomes
- Decisional Conflict Scale (DCS) Score (Baseline)
- Decisional Conflict Scale (DCS) Score (Month 3)
- Decisional Conflict Scale (DCS) Score (Month 6)
- Patient HER2-Targeted ADC Related Side Effect Pre-Test Score (Baseline)
- Patient HER2-Targeted ADC Related Side Effect Post-Test Score (Month 3)
- Patient HER2-Targeted ADC Related Side Effect Post-Test Score (Month 6)
- Clinician HER2-Targeted ADC Related Side Effect Pre-Test Score (Baseline)
- Clinician HER2-Targeted ADC Related Side Effect Post-Test Score (Month 3)
Eligibility information
Study locations
- NYU Langone Health, New York, New York 10016 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.